CBT Advisors is a consultancy founded in 2003 working with private biotechnology, life sciences and medical device companies on storytelling and strategy. We are based in Cambridge, MA. Much of the firm’s work focuses on drafting business sections for NASDAQ IPOs. As of October, 2020, fifty-nine clients have gone public, raising $5.9 billion. Recent IPO clients have included Zentalis, Repare, Black Diamond, Pliant Therapeutics, iTeos, Legend Biotech and Allovir. Earlier clients included CRISPR Therapeutics, Karuna Therapeutics, Alector, Translate Bio, ArgenX, Personalis, Inspire Medical, Vapotherm and others.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cbtadvisors.com
Cbt Advisors Questions
Cbt Advisors's website is cbtadvisors.com
Cbt Advisors's LinkedIn profile is https://www.linkedin.com/company/cbt-advisors
Cbt Advisors's industry is
Biotechnology Research
Cbt Advisors's top competitors are
Rhino Therapeutics, Inc. A Curie.bio Company,
Modiblast,
Aipto,
Myracle Therapeutics,
Fitebac Technologies,
Forbion,
Curie.bio,
Tvm Capital Life Science,
Blockcom,
Orbimed.
Cbt Advisors's categories are Biotechnology Research
Cbt Advisors's founding year is 2003
